Clinical Trial Update: Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study [Phase 2]

View source ↗

Summary

Phase 2 AMOUR trial evaluating aflibercept for macular edema due to underlying retinitis pigmentosa has completed and results were posted in May 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macular Edema
• Retinitis Pigmentosa

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Moorfields Eye Hospital NHS Foundation Trust | Conditions: Macular Oedema, Retinitis Pigmentosa | Phase 2 | Status: COMPLETED | Results posted: 2024-05-06